Medicxi Ventures Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Medicxi Ventures Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81M	Hold	7,464,572	–	–	45.65%	1
2026 Q1	$82.9M	Hold	7,464,572	–	–	8.45%	3
2025 Q4	$124M	Hold	7,464,572	–	–	14.83%	2
2025 Q3	$87.9M	Hold	7,464,572	–	–	11.8%	2
2025 Q2	$71.6M	Hold	7,464,572	–	–	16.75%	2
2025 Q1	$46.8M	Hold	7,464,572	–	–	10.69%	3
2024 Q4	$60.6M	Hold	7,464,572	–	–	11.46%	3
2024 Q3	$135M	Hold	7,464,572	–	–	25.52%	2
2024 Q2	$76.9M	Hold	7,464,572	–	–	22.93%	2
2024 Q1	$79.3M	Buy	7,464,572 +3,703,703	+98%	+$31.5M	17.65%	2
2023 Q4	$34.3M	Hold	3,760,869	–	–	11.59%	3
2023 Q3	$39M	Hold	3,760,869	–	–	12.45%	3
2023 Q2	$53.9M	Buy	3,760,869 +1,276,595	+51%	+$14.7M	15.09%	3
2023 Q1	$17.7M	Hold	2,484,274	–	–	7.6%	6
2022 Q4	$27.9M	Hold	2,484,274	–	–	11.71%	4
2022 Q3	$27.5M	Buy	2,484,274 +33,595	+1%	+$320K	11.46%	5
2022 Q2	$20.7M	Buy	2,450,679 +382,818	+19%	+$3.94M	8.59%	5
2022 Q1	$28.1M	Hold	2,067,861	–	–	7.62%	5
2021 Q4	$40.7M	Hold	2,067,861	–	–	10.18%	5
2021 Q3	$66.4M	Hold	2,067,861	–	–	14.44%	2
2021 Q2	$70M	Hold	2,067,861	–	–	12.54%	2
2021 Q1	$77.7M	Hold	2,067,861	–	–	45.23%	1
2020 Q4	$68.7M	Hold	2,067,861	–	–	39.92%	1
2020 Q3	$75.8M	Hold	2,067,861	–	–	36.21%	2
2020 Q2	$68.1M	Hold	2,067,861	–	–	41.83%	1
2020 Q1	$53.4M	Hold	2,067,861	–	–	69.76%	1
2019 Q4	$64.4M	Buy	+2,067,861	New	+$52M	39.46%	2

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Medicxi Ventures Management's PHAT Position: Q2 2026 in Review

Medicxi Ventures Management held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 7,464,572 shares worth $81M. The position accounts for 45.65% of the portfolio, ranked #1.

Medicxi Ventures Management first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $135M in Q3 2024. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Medicxi Ventures Management held 7,464,572 shares of Phathom Pharmaceuticals worth $81M as of Q2 2026.
Medicxi Ventures Management left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
Phathom Pharmaceuticals made up 45.65% of Medicxi Ventures Management's portfolio in Q2 2026, its #1 holding.
Medicxi Ventures Management first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
Medicxi Ventures Management's Phathom Pharmaceuticals position peaked at $135M in Q3 2024.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Medicxi Ventures Management's 13F filing for Q2 2026, filed 4 Aug 2026.